Skip to main content

Lupus

      RT @ericdeinmd: @jhrheumatology Dr. Petri - if Lupus nephritis biopsy is very active start a dual therapy with MMF right

      Eric Dein ericdeinmd

      3 years 10 months ago
      @jhrheumatology Dr. Petri - if Lupus nephritis biopsy is very active start a dual therapy with MMF right away. ▶️ If not, continue to re-evaluate at 3 and 6 months for early combo therapy #ACR21 Great Debate @Rheumnow https://t.co/ctKdbWTMqy
      RT @drdavidliew: How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVI

      David Liew drdavidliew

      3 years 10 months ago
      How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVID-19 vaccination? Better chance of response if: - RA or SLE, not AAV or IIM - high serum IgG pre-last RTX - longer time since last RTX Israeli data #ACR21 ABST0437 @RheumNow https://t.co/yyuFd0eDH6
      RT @ericdeinmd: @jhrheumatology Dr. Petri at #ACR21 Great Debate.
      Safety issues with Voclosporin:
      1) Nephrotoxicity
      2) I

      Eric Dein ericdeinmd

      3 years 10 months ago
      @jhrheumatology Dr. Petri at #ACR21 Great Debate. Safety issues with Voclosporin: 1) Nephrotoxicity 2) Infection 3) CV Risk Factors 4) Malignancy 5) Neurologic toxicity 6) Osteoporosis 7) Drug interactions 8) Deaths 9) Pregnancy contraindication @RheumNow https://t.co/wjluivmKNt
      RT @KDAO2011: Dr. Chambers review @MotherToBaby prospective data on HCQ use in pregnancy (n=279):
      👉no major defects (

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Dr. Chambers review @MotherToBaby prospective data on HCQ use in pregnancy (n=279): 👉no major defects (regardless of dose) 👉no oral clefts 👉SGA slightly lower in exposed group b/c of underlying dz 👉no case of retinopathy in babies after 1 year f/u @rheumnow #Pregnancy https://t.co/vw2eryFgro
      RT @Yuz6Yusof: #Abstr0076 #ACR21 Can we predict #thrombosis in #lupus patients? Predictors of serology transition at 5yr

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      #Abstr0076 #ACR21 Can we predict #thrombosis in #lupus patients? Predictors of serology transition at 5yrs: ✅LAC+ to LAC-:Afro-American,HCQ and normal C3 ⛔️LAC+ to 🩸Clot:Obesity, low C3 and not on HCQ Data need in those with Triple Positivity @RheumNow https://t.co/byeL5NjVUS https://t.co/CchtZir2GN
      RT @Yuz6Yusof: Either we need to review the Yearly PAP cervical screening in SLE women or work hard to improve patient a

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      Either we need to review the Yearly PAP cervical screening in SLE women or work hard to improve patient awareness. Suspect the latter as time between tests was over 4 years late 😱 and 2.7% developed cancer #ACR21 #Abstr0133 @RheumNow https://t.co/wm01MfoFjf https://t.co/blD8WafZsE
      RT @Yuz6Yusof: #ACR21 Year in Review. Caielli et al. showed in some patients with #lupus, red blood cells retained their

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      #ACR21 Year in Review. Caielli et al. showed in some patients with #lupus, red blood cells retained their mitochondria (Mito+ RBCs) and their frequency correlated with disease activity and blood⬆️IFN @RheumNow https://t.co/ZixgAbOWJ0 https://t.co/hkTWE4m7Ph
      RT @KDAO2011: 👉Voclosporin for SLE: rapid control of proteinuria (50% reduction over 29 days in UPCR w/o high side ef

      TheDaoIndex KDAO2011

      3 years 10 months ago
      👉Voclosporin for SLE: rapid control of proteinuria (50% reduction over 29 days in UPCR w/o high side effects) @rheumnow #YearInReview #ACR21 Are you all starting to use this drug now? It has helped my patients; pretty well tolerated. https://t.co/zqJRsjnV4n
      RT @ericdeinmd: AURORA 1, Year in Review: Voclosporin as add-on therapy lupus nephritis. Approved in 1/2021 for active l

      Eric Dein ericdeinmd

      3 years 10 months ago
      AURORA 1, Year in Review: Voclosporin as add-on therapy lupus nephritis. Approved in 1/2021 for active lupus nephritis, very positive data @rheumnow #ACR21 https://t.co/rudYD1OC59
      Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.
      Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.
      The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021.  Below is a listing of some of their best studies for you to review and look for in the meeting. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look. Aurinia
      ×